FLOLAN epoprostenol sodium 1.5 mg powder for injection vial with diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

flolan epoprostenol sodium 1.5 mg powder for injection vial with diluent vial

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

FLOLAN epoprostenol sodium 500 microgram powder for injection vial with diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

flolan epoprostenol sodium 500 microgram powder for injection vial with diluent vial

glaxosmithkline australia pty ltd - epoprostenol sodium, quantity: 0.531 mg (equivalent: epoprostenol, qty 0.5 mg) - injection, powder for - excipient ingredients: sodium chloride; sodium hydroxide; mannitol; glycine - flolan is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with: idiopathic pulmonary arterial hypertension; familial pulmonary arterial hypertension; pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

Epoprostenol 500microgram powder and solvent (pH10.5) for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

epoprostenol 500microgram powder and solvent (ph10.5) for solution for infusion vials

ph10.5) for solution for infusion vials (advanz pharma - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

Epoprostenol 1.5mg powder and solvent (pH10.5) for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

epoprostenol 1.5mg powder and solvent (ph10.5) for solution for infusion vials

ph10.5) for solution for infusion vials (advanz pharma - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

Epoprostenol 500microgram powder (pH12) for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

epoprostenol 500microgram powder (ph12) for solution for infusion vials

ph12) for solution for infusion vials (sun pharmaceutical industries europe b.v. - epoprostenol sodium - powder for solution for infusion - 500microgram

Epoprostenol 1.5mg powder (pH12) for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

epoprostenol 1.5mg powder (ph12) for solution for infusion vials

ph12) for solution for infusion vials (sun pharmaceutical industries europe b.v. - epoprostenol sodium - powder for solution for infusion - 1.5mg

Epoprostenol for I.V. Injection 0.5 mg "Janssen" (エポプロステノール静注用0.5mg「ヤンセン」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

epoprostenol for i.v. injection 0.5 mg "janssen" (エポプロステノール静注用0.5mg「ヤンセン」)

janssen pharmaceutical k.k. - epoprostenol sodium - injection

Epoprostenol for I.V. Injection 1.5 mg "Janssen" (エポプロステノール静注用1.5mg「ヤンセン」) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

epoprostenol for i.v. injection 1.5 mg "janssen" (エポプロステノール静注用1.5mg「ヤンセン」)

janssen pharmaceutical k.k. - epoprostenol sodium - injection

EPOPROSTENOL DREHM Ireland - English - HPRA (Health Products Regulatory Authority)

epoprostenol drehm

drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 500 microgram

EPOPROSTENOL DREHM Ireland - English - HPRA (Health Products Regulatory Authority)

epoprostenol drehm

drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 1.5 milligram